Form 4: Alignment Healthcare Executive Sells 30,000 Shares Under 10b5-1 Plan

Dawn Christine Maroney, President of Markets at Alignment Healthcare, sold 30,000 shares of common stock at a weighted average price of $11.352 per share on November 15, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Dawn Christine Maroney, President of Markets at Alignment Healthcare, executed a sale of 30,000 shares of the company's common stock on November 15, 2024.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2024.
• The shares were sold at a weighted average price of $11.352 per share, with individual transaction prices ranging from $10.97 to $11.56.
• Following the transaction, Maroney directly owns 1,696,097 shares of Alignment Healthcare common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine executive stock sale under a pre-arranged plan. It doesn't indicate any positive or negative outlook for the company.

Negatives

• An executive selling shares could be perceived negatively by some investors, although this sale was under a pre-arranged plan.

Risks

• Executive stock sales, even under pre-arranged plans, can sometimes create uncertainty in the market.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often conducted under pre-arranged trading plans to avoid accusations of insider trading. This transaction is not unusual and is part of normal market activity.

Comparison to Industry Standards

• Executive stock sales are a common practice across the industry, with many executives using 10b5-1 plans to manage their personal finances while avoiding insider trading concerns.
• Comparable companies such as Humana, UnitedHealth Group, and CVS Health also see regular Form 4 filings from their executives.
• The volume of shares sold and the price range are within typical parameters for such transactions.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Alignment Healthcare, executive stock sale, Form 4, 10b5-1 plan, Dawn Christine Maroney, insider trading, stock transaction